经鼻蒸发降温对院外心脏骤停功能性神经结局的影响:PRINCESS随机临床试验
PRINCESS试验为研究者发起的国际多中心随机临床研究,结局评估设盲,由7个欧洲国家的急救医疗服务实施,2010年7月至2018年1月纳入677例旁观者目击的院外心脏骤停患者,随机分为经鼻蒸发降温组(n=343)和标准治疗组(n=334),两组入院后均接受32°C至34°C全身治疗性低温24小时。主要终点为90天良好神经结局(CPC 1-2),干预组56/337(16.6%) vs 对照组45/334(13.5%),差异3.1%(95%CI -2.3%至8.5%),RR 1.23(95%CI 0.86-1.72),P=0.25,未达统计学显著。次要终点90天生存率干预组60/337(17.8%) vs 对照组52/334(15.6%),差异2.2%(95%CI -3.4%至7.9%),RR 1.14(95%CI 0.81-1.57),P=0.44。核心体温低于34°C的中位时间干预组105分钟 vs 对照组182分钟(P<0.001)。结论认为经鼻蒸发降温相比常规治疗未显著改善90天良好神经结局。
要点
- 院外心脏骤停患者中,经鼻蒸发降温组90天良好神经结局(CPC 1-2)为16.6%(56/337),对照组为13.5%(45/334),差异未达统计学显著(P=0.25)。
- 经鼻蒸发降温可加速降温:核心体温低于34°C的中位时间干预组105分钟 vs 对照组182分钟(P<0.001)。
- 90天生存率干预组17.8%(60/337) vs 对照组15.6%(52/334),差异未达统计学显著(P=0.44)。
- 干预组最常见的装置相关不良事件为轻微鼻出血,发生于13%(45/337)的患者;7天内不良事件率两组相似。
适用人群与场景
- 旁观者目击的院外心脏骤停患者,共677例随机(干预组343例,对照组334例),中位年龄65岁,女性172例(25%)。
- 由7个欧洲国家的急救医疗服务实施,时间为2010年7月至2018年1月,最终随访至2018年4月29日。
处置流程与药物剂量
- 干预组在心肺复苏期间(院前)接受经鼻蒸发降温;两组患者入院后均接受32°C至34°C全身治疗性低温24小时。
- 对照组接受标准治疗,降温在入院后启动。
研究设计与关键结果
- 研究类型:研究者发起的国际多中心随机临床研究,结局评估设盲;纳入677例旁观者目击的院外心脏骤停患者,671例完成试验。
- 主要终点:90天良好神经结局(CPC 1-2),干预组56/337(16.6%) vs 对照组45/334(13.5%),差异3.1%(95%CI -2.3%至8.5%),RR 1.23(95%CI 0.86-1.72),P=0.25。
- 次要终点:90天生存率干预组60/337(17.8%) vs 对照组52/334(15.6%),差异2.2%(95%CI -3.4%至7.9%),RR 1.14(95%CI 0.81-1.57),P=0.44。
- 次要终点:核心体温低于34°C的中位时间干预组105分钟 vs 对照组182分钟(P<0.001)。
- 不良事件:干预组轻微鼻出血45/337(13%);7天内不良事件率两组相似。
证据类型、等级与局限
- 证据类型:国际多中心随机临床研究(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在院外心脏骤停患者中,院前启动经鼻蒸发降温相比入院后降温未显著改善90天良好神经结局,作者结论认为未达统计学显著改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Therapeutic hypothermia may increase survival with good neurologic outcome after cardiac arrest. Trans-nasal evaporative cooling is a method used to induce cooling, primarily of the brain, during cardiopulmonary resuscitation (ie, intra-arrest).
OBJECTIVE: To determine whether prehospital trans-nasal evaporative intra-arrest cooling improves survival with good neurologic outcome compared with cooling initiated after hospital arrival.
DESIGN, SETTING, AND PARTICIPANTS: The PRINCESS trial was an investigator-initiated, randomized, clinical, international multicenter study with blinded assessment of the outcome, performed by emergency medical services in 7 European countries from July 2010 to January 2018, with final follow-up on April 29, 2018. In total, 677 patients with bystander-witnessed out-of-hospital cardiac arrest were enrolled.
INTERVENTIONS: Patients were randomly assigned to receive trans-nasal evaporative intra-arrest cooling (n = 343) or standard care (n = 334). Patients admitted to the hospital in both groups received systemic therapeutic hypothermia at 32°C to 34°C for 24 hours.
MAIN OUTCOMES AND MEASURES: The primary outcome was survival with good neurologic outcome, defined as Cerebral Performance Category (CPC) 1-2, at 90 days. Secondary outcomes were survival at 90 days and time to reach core body temperature less than 34°C.
RESULTS: Among the 677 randomized patients (median age, 65 years; 172 [25%] women), 671 completed the trial. Median time to core temperature less than 34°C was 105 minutes in the intervention group vs 182 minutes in the control group (P < .001). The number of patients with CPC 1-2 at 90 days was 56 of 337 (16.6%) in the intervention cooling group vs 45 of 334 (13.5%) in the control group (difference, 3.1% [95% CI, -2.3% to 8.5%]; relative risk [RR], 1.23 [95% CI, 0.86-1.72]; P = .25). In the intervention group, 60 of 337 patients (17.8%) were alive at 90 days vs 52 of 334 (15.6%) in the control group (difference, 2.2% [95% CI, -3.4% to 7.9%]; RR, 1.14 [95% CI, 0.81-1.57]; P = .44). Minor nosebleed was the most common device-related adverse event, reported in 45 of 337 patients (13%) in the intervention group. The adverse event rate within 7 days was similar between groups.
CONCLUSIONS AND RELEVANCE: Among patients with out-of-hospital cardiac arrest, trans-nasal evaporative intra-arrest cooling compared with usual care did not result in a statistically significant improvement in survival with good neurologic outcome at 90 days.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01400373.
参考来源
- Nordberg P, Taccone FS, Truhlar A, et al. Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome in Out-of-Hospital Cardiac Arrest: The PRINCESS Randomized Clinical Trial. JAMA. 2019. PMID: 31063573. doi:10.1001/jama.2019.4149
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。